W&T Offshore, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by W&T Offshore, Inc. (NYSE: WTI) on May 1, 2023, reporting events that occurred on April 28, 2023. The filing focuses on corporate governance changes, specifically the expansion of the Board of Directors and the appointment of a new independent director.
Financial Metrics
The filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. This report is strictly a disclosure of a corporate event and does not provide a financial performance update.
Material Changes
- Board Expansion: The Board of Directors voted to expand its size to five members.
- New Appointment: Dr. Nancy Chang was appointed to fill the vacancy on the Board effective April 28, 2023.
- Committee Assignments: Dr. Chang was appointed to the Audit Committee and the Nominating and Corporate Governance Committee. She was also named Chair of the Environmental, Safety and Governance (ESG) Committee.
- Independence: The Board determined Dr. Chang meets the independence requirements of the New York Stock Exchange and the Company's standards.
Management Commentary, Risks, and Unusual Items
Compensation and Agreements: Dr. Chang will receive standard non-employee director compensation as detailed in the Company's 2023 Proxy Statement. The Company entered into an Indemnification Agreement with Dr. Chang, indemnifying her to the fullest extent permitted under Texas law and advancing expenses related to proceedings.
Background: Dr. Chang brings extensive experience in biotechnology and investment management, having previously served as CEO of Ansun Biopharma, Founder of Apex Capital, and Co-Founder of Tanox, Inc. She holds a Ph.D. from Harvard Medical School.
Regulatory Disclosure: The press release announcing this appointment is furnished under Item 7.01 (Regulation FD) and is not deemed "filed" for purposes of Section 18 of the Exchange Act.
Key Facts for Investor Verification
- Verify the specific compensation terms for Dr. Chang in the Company's 2023 Proxy Statement.
- Confirm the effective date of Dr. Chang's service (April 28, 2023) and her tenure duration (until the next annual meeting or earlier termination).
- Review the full text of the Indemnification Agreement filed as Exhibit 10.3 to the August 8, 2022 Form 8-K.
- Note that this filing contains no financial data; investors should refer to the most recent 10-Q or 10-K for financial performance.